Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulixertinib for Patients With Histiocytic Neoplasms
NCT06411821Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ulixertinib in Histiocytic Neoplasm (HN) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate at 1 year. Started May 2024; status: recruiting.
02
Drugs
ulixertinib
03
Conditions
Histiocytic Neoplasm (HN)
Beyond the preview
Go deeper on NCT06411821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411821.